VAERS Explorer
Back to explore

Report #2881739

Received Jan 13, 2026

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex
Unknown
Age
Age unknown
State
NY
Recovered
Unknown
Vaccinated
Jan 6, 2026
Onset
Jan 6, 2026
Days to onset
0
Hospital days
—

Vaccines (1)

TypeNameManufacturerDoseLotRoute / Site
MENMENINGOCOCCAL (NO BRAND NAME)UNKNOWN MANUFACTURERUNK—OT

Symptoms (1)

Product storage error

Symptom narrative

electricity went out, max/Low temperature reached: 27.7 C or 81 F duration and was administered to the patient with no reported adverse event; Initial information received on 08-Jan-2026 regarding an unsolicited valid non-serious case received from a other health professional via call center. This case involves an unknown demographics patient who had experienced an event electricity went out, Meningococcal A-C-Y-W135 (T CONJ) Vaccine [Menquadfi] max/low temperature reached: 27.7 celsius or 81 fahrenheit duration and was administered to the patient. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. On 06-Jan-2026, the patient received a unknow dose of suspect Meningococcal A-C-Y-W135 (T CONJ) Vaccine Solution for injection (strength, route, batch number, expiry date and administration site: unknown) for prophylactic vaccination was exposed to temperature excursion, electricity went out, and vaccine max/low temperature reached: 27.7 celsius or 81 fahrenheit duration and was administered to the patient (Poor quality product administered) (latency: same day). Action taken: not applicable. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.